Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Approving Complex Generics Pre-ANDA Meeting Requests At Higher Rates

Uptrend Could Signal Surge In Complex-Generic Approvals

Executive Summary

Approval rates for complex-drug pre-ANDA meeting requests are climbing. FDA’s hope is that the meetings will hasten approvals of these hard-to-manufacture generics, which could put a dent in US healthcare costs.
Advertisement

Related Content

US FDA’s Pre-ANDA Advice On Correspondence, Meetings And Product-Specific Guidance
FDA Urges Development Of Generic Alternatives To Bring Down Prices Of Complex Drugs
ANDA Sponsors Need To 'Slow Down' And Focus On Quality, US FDA Generics Director Says
Pre-ANDA Meetings Proving Tough To Get – Nearly Half Of Requests Denied
US FDA Commits To Meeting With Complex ANDA Sponsors, Works Hard To Avoid It
FDA Web Portal Eases Pre-ANDA Meeting Request Process

Topics

Advertisement
UsernamePublicRestriction

Register

PS123925

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel